2nd May 2017
Nuformix has entered into an agreement with Fibrofind to conduct pre-clinical development work for its NXP002 programme. Nuformix Chief Executive Officer Dr Dan Gooding commented “We’re extremely lucky to have had the chance to work with Fibrofind since its inception – the quality of its people, knowledge and expertise make it a unique place to study fibrosis. The first phase of our programme has concluded positively in multiple fibrotic conditions and we’re very excited by the results we’ve seen.”